论文部分内容阅读
目的观察安脱达尘螨疫苗特异性免疫治疗变应性鼻炎的疗效及安全性。方法选取变应原皮肤点刺试验均为阳性的变应性鼻炎患者80例,均行安脱达特异性免疫治疗。观察患者临床症状和体征积分及不良反应情况。结果通过2年治疗,症状和体征积分比较,治疗前为(9.25±2.89)分,高于治疗后的(4.05分±1.28)分,差异有统计学意义(P<0.01)。结论安脱达特异性免疫治疗,对变应性鼻炎症状改善明显,疗效确切,值得临床推广应用。
Objective To observe the efficacy and safety of the immunotherapy against dust-allergic rhinitis induced by dust-damaging vaccine. Methods Allergen skin prick tests were all positive in 80 patients with allergic rhinitis, antiretroviral immunotherapy. Observed patients with clinical symptoms and signs score and adverse reactions. Results After 2 years of treatment, the scores of symptoms and signs were (9.25 ± 2.89) before treatment and higher than those after treatment (4.05 ± 1.28), the difference was statistically significant (P <0.01). Conclusion Amiodar immunosuppressive therapy can improve the symptoms of allergic rhinitis with definite curative effect and is worthy of clinical application.